OTTAWA — The prospect of Sandoz profiting from a nationwide drug shortage caused by its Canadian subsidiary shows a “shocking” failure of federal leadership, critics charge. “It’s shocking that the very company that caused the immediate crisis is the one that could benefit,” said Libby Davies, the federal NDP health critic. “Patients and Canadians are being held captive, and I just don’t think people will tolerate this.”